Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer

Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer is a phase 2, interventional study registered as NCT06751394 by Sixth Affiliated Hospital, Sun Yat-sen University, with a registry enrolment figure of 44 participants, started 2025-01-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: PD-1 antibody (Toripalimab); Capecitabine; Oxaliplatin; Irinotecan; Radiation; surgery. Conditions listed: Recurrent Rectal Cancer. Primary outcome: Pathological complete response rate. Colorectal eligibility wording from the registry: "Active inflammatory bowel disease or other colorectal diseases that lead to chronic diarrhea". Sites: China. No results are recorded here; the registry entry is the source.